Home › Targets › EEF2
Radioligand therapy target profile

EEF2: IHC Expression in Cancer and Radioligand Target Profile

eukaryotic translation elongation factor 2 · Ensembl ENSG00000167658 · Data updated 2026-11-01

EEF2, eukaryotic translation elongation factor 2, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, EEF2 staining is highest in endometrial cancer (100% of samples positive), testicular cancer (100% of samples positive) and colorectal cancer (100% of samples positive). Clinical status: FDA-approved drug (any modality).

Is EEF2 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze EEF2 free
LocalizationCell-Surface
Top cancer (IHC)Endometrial Cancer
InternalizationNot assessed
Clinical stageFDA-approved drug (any modality)
Active trialsSee ClinicalTrials.gov
Cancer association (Open Targets)0.62

Is EEF2 a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

EEF2 IHC staining by cancer type

Protein expression of EEF2 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Endometrial Cancer1.00High100%
Testicular Cancer0.97High100%
Colorectal Cancer0.97High100%
Breast Cancer0.94High100%
Gastric Cancer0.86High100%
Lymphoma0.85High100%
Head and Neck Cancer0.83High100%
Thyroid Cancer0.83High100%
Pancreatic Cancer0.83High100%
Melanoma0.82High100%
Bladder Cancer0.82High100%
Cervical Cancer0.82High100%
Prostate Cancer0.82High100%
Skin Cancer0.80High100%
Ovarian Cancer0.73High100%
Glioma0.70High91%
Neuroendocrine Tumors0.67High100%
Lung Cancer0.67High100%
Liver Cancer0.56High83%
Kidney Cancer0.53High80%

Is EEF2 internalized?

Nuclens has not yet extracted internalization evidence for EEF2. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.

EEF2 clinical trials

FDA-approved drug (any modality). Nuclens hasn't indexed trials for EEF2 yet. Search ClinicalTrials.gov for EEF2 trials.

EEF2 normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See EEF2 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

EEF2 gene essentiality (DepMap)

CRISPR knockout effect across 1258 cancer cell lines: -2.71 (essential, below −0.5). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related endometrial cancer radioligand targets

HER3 (ERBB3) · c-MET (MET) · EGFR · EPCAM · SSTR2 · ITGAV · B7-H3 (CD276) · STEAP2

See all radioligand therapy targets in endometrial cancer.

See how EEF2 ranks against 15,000 targets for your indication.

Analyze EEF2 free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is EEF2 the right target for your program? · 5 free analyses, no card Analyze EEF2 free